Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Immunohistochemistry Biomarkers in Nonmuscle Invasive Bladder Cancer

Immunohistochemistry Biomarkers in Nonmuscle Invasive Bladder Cancer Bladder cancer (BCa) is the most frequent urinary tract neoplasm. BCa results in significant mortality when the disease presents as muscle invasive. Around 75% to 80% of patients present with nonmuscle invasive bladder cancer (NMIBC), but recurrence and progression are significant issues, compelling current guidelines to recommend long-term surveillance. There is therefore an urgent and unmet need to identify and validate accurate biomarkers for the detection of disease recurrence to improve quality of life for the patients and reduce costs for health care providers, while maintaining or improving current outcomes. In this review, 38 publications on immunohistochemistry prognostic biomarkers, that were studied may be related in nonmuscle invasive bladder cancer, have been analyzed. The studies were organized according to the evaluated marker and their findings. It was demonstrated that the combination of independent complementary biomarkers could allow a more accurate prognosis than an isolated marker. Biomarkers, including p53, Ki-67, and CK20, with classic and prognostic factors with recurrence and novel markers such as EN2 may provide a more accurate prediction of outcome compared with any single marker, improving risk stratification and clinical management of patients with BCa. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Immunohistochemistry Biomarkers in Nonmuscle Invasive Bladder Cancer

Download PDF
6 pages

Loading next page...
 
/lp/wolters-kluwer-health/immunohistochemistry-biomarkers-in-nonmuscle-invasive-bladder-cancer-ANgSiNfj44

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1062-3345
eISSN
1533-4058
DOI
10.1097/PAI.0000000000000280
pmid
26574637
Publisher site
See Article on Publisher Site

Abstract

Bladder cancer (BCa) is the most frequent urinary tract neoplasm. BCa results in significant mortality when the disease presents as muscle invasive. Around 75% to 80% of patients present with nonmuscle invasive bladder cancer (NMIBC), but recurrence and progression are significant issues, compelling current guidelines to recommend long-term surveillance. There is therefore an urgent and unmet need to identify and validate accurate biomarkers for the detection of disease recurrence to improve quality of life for the patients and reduce costs for health care providers, while maintaining or improving current outcomes. In this review, 38 publications on immunohistochemistry prognostic biomarkers, that were studied may be related in nonmuscle invasive bladder cancer, have been analyzed. The studies were organized according to the evaluated marker and their findings. It was demonstrated that the combination of independent complementary biomarkers could allow a more accurate prognosis than an isolated marker. Biomarkers, including p53, Ki-67, and CK20, with classic and prognostic factors with recurrence and novel markers such as EN2 may provide a more accurate prediction of outcome compared with any single marker, improving risk stratification and clinical management of patients with BCa.

Journal

Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health

Published: Mar 1, 2017

References

  • Trends in mortality from urologic cancers in Europe, 1970-2008
  • Epidemiology and risk factors of urothelial BCa
  • EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013
  • Mesenchymal tumours of the bladder and prostate: an update
  • Association between smoking and risk of BCa among men and women
  • The magnitude of the association between smoking and the risk of developing cancer in Brazil: a multicenter study
  • Comprehensive molecular characterization of urothelial bladder carcinoma
  • Contemporary management of low-risk BCa
  • BCa detection and monitoring: assessment of urine- and blood-based marker tests
  • Urine markers for detection and surveillance of BCa
  • Superficial papillary urothelial neoplasms of the bladder (PTA E PT1): correlation of expression of P53, KI-67 and CK20 with histologic grade, recurrence and tumor progression
  • Prognostic versus predictive value of biomarkers in oncology
  • Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder
  • Predictive markers in bladder cancer: do we have molecular markers ready for clinical use?
  • Livin, Survivin and Caspase 3 as early recurrence markers in non-muscle-invasive BCa
  • UHRF1 is associated with tumor recurrence in non-muscle-invasive bladder cancer
  • The prognostic value of P-cadherin in non-muscle-invasive BCa
  • Absent CD44v6 expression is an independent predictor of poor urothelial BCa outcome
  • Clinical significance of CD24 as a predictor of BCa recurrence
  • Association of oncofetal protein expression with clinical outcomes in patients with urothelial carcinoma of the bladder
  • Ki67 and TP53 expressions predict recurrence of non-muscle-invasive BCa
  • Expression of fibroblast growth factor receptor 3 in the recurrence of non-muscle-invasive urothelial carcinoma of the bladder
  • UHRF1 is a novel molecular marker for diagnosis and the prognosis of BCa
  • AEG-1 is associated with tumor progression in nonmuscle-invasive BCa
  • Expression of histone deacetylases 1, 2 and 3 in urothelial BCa
  • Expression of Engrailed-2 (EN2) protein in BCa and its potential utility as a urinary diagnostic biomarker
  • Overexpression of HMGA2 in BCa and its association with clinicopathologic features and prognosis HMGA2 as a prognostic marker of BCa
  • Increased expression of HMGB1 is associated with poor prognosis in human BCa
  • Expression of CHD1L in BCa and its influence on prognosis and survival
  • High expression level of BLCA-4 correlates with poor prognosis in human BCa
  • Prognostic comparison of proliferation markers and World Health Organization 1973/2004 grades in urothelial carcinomas of the urinary bladder
  • Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial BCa
  • HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in BCa
  • Clinicopathological correlates of Gli1 expression in a population-based cohort of patients with newly diagnosed BCa
  • Lower cyclooxygenase-2 expression is associated with recurrence of solitary non-muscle invasive bladder carcinoma
  • USP28 is a potential prognostic marker for BCa
  • p53 predictive value for pT1-2N0 disease at radical cystectomy
  • Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy
  • p53 immunohistochemistry in bladder cancer—a new approach to an old question
  • Altered p53 and pRb expression is predictive of response to BCG treatment in T1G3 bladder cancer
  • A six-week course of bacillus Calmette-Guerin prophylaxis is insufficient to prevent tumor recurrence in non muscle invasive bladder cancer with strong-positive expression of p53
  • Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?
  • p53 expression in patients with advanced urothelial cancer of the urinary bladder
  • Molecular grade (FGFR3/MIB1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer
  • Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer
  • Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?
  • Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guerin
  • Expression of cell cycle-associated proteins in non-muscle-invasive bladder cancer: correlation with intravesical recurrence following transurethral resection
  • Engrailed-2 (EN2): a tumor specific urinary biomarker for the early diagnosis of prostate cancer